A Delaware biopharmaceutical manufacturer, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), is partnering with the FDA to regulate their new biopharmaceutical manufacturing training and research facility.
The agreement, referred to as a Creative Research and Development Agreement (CRADA), will provide the legal framework for the biopharmaceutical network and allow for industry-wide collaboration at NIIMBL’s new headquarters in Newark, Delaware.
“The NIIMBL space will be a neutral 3rd party space, if you will, where various members of our ecosystem can come together and work collaboratively on these projects to advance the technologies, to advance workforce training activities,” said Kelvin Lee, the NIIMBL Institute Director and University of Delaware Gore Professor of Chemical Engineering.
The facility will open at the University of Delaware’s STAR campus in the next year with the Delaware Biotechnology Institute and the University of Delaware’s biomedical engineering program.
There are approximately 60 NIIMBL biopharmaceutical manufacturing projects currently that are focusing on sterilizing medication and advancing technologies for manufacturing cell therapies and gene therapies.
DuPont recently opened a global industrial biotech headquarters in Wilmington, Delaware. The space was strategically created as one collaborative place for scientists, customers, and businesspeople to stimulate innovation and communication throughout our region’s life sciences community.